Publique en esta revista
Información de la revista
Vol. 3. Núm. 3.
Páginas 95-97 (Mayo - Junio 2007)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 3. Núm. 3.
Páginas 95-97 (Mayo - Junio 2007)
Editorial
DOI: 10.1016/S1699-258X(07)73674-4
Acceso a texto completo
Seguridad cardiovascular de los antiinflamatorios no esteroideos. Luces y sombras
Visitas
...
Luis A. García Rodrígueza,??
Autor para correspondencia
lagarcia@ceife.es

Correspondencia: Dr. L.A. García Rodríguez. Centro Español de Investigación Farmacoepidemiológica (CEIPE). Almirante, 28, 2.o. 28004 Madrid. España.
, Antonio González-Pérezb
a Centro Español de Investigación Farmacoepidemiológica (CEIFE). Madrid. España
b Departamento de Genómica Estructural. Nexcodex SL. Sevilla. España
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A.G. Johnson, T.V. Nguyen, R.O. Day.
Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.
Ann Intern Med, 121 (1994), pp. 289-300
[2.]
E.R. Heerdink, H.G. Leufkens, R.M. Herings, J.P. Ottervanger, B.H. Stricker, A. Bakker.
NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.
Arch InternMed, 158 (1998), pp. 1108-1112
[3.]
J. Page, D. Henry.
Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an unrecognized public health problem.
Arch Intern Med, 160 (2000), pp. 777-784
[4.]
L.A. García Rodríguez, C. Varas, C. Patrono.
Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women.
Epidemiology, 11 (2000), pp. 382-387
[5.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, VIGOR Study Group, et al.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med, 343 (2000), pp. 1520-1528
[6.]
B.F. McAdam, F. Catella-Lawson, I.A. Mardini, S. Kapoor, J.A. Lawson, G.A. Fitzgerald.
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
Proc Natl Acad Sci USA, 96 (1999), pp. 272-277
[7.]
F. Catella-Lawson, B. McAdam, B.W. Morrison, S. Kapoor, D. Kujubu, L. Antes, et al.
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
J Pharmacol Exp Ther, 289 (1999), pp. 735-741
[8.]
R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, et al.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
N Engl J Med, 352 (2005), pp. 1092-1102
[9.]
S.A. Reines, G.A. Block, J.C. Morris, G. Liu, M.L. Nessly, C.R. Lines, et al.
Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study.
Neurology, 62 (2004), pp. 66-71
[10.]
S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, Adenoma Prevention with Celecoxib (APC) Study Investigators, et al.
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
N Engl J Med, 352 (2005), pp. 1071-1080
[11.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial: Celecoxib Long-term Arthritis Safety Study.
JAMA, 284 (2000), pp. 1247-1255
[12.]
W.B. White, G. Faich, A. Whelton, C. Maurath, N.J. Ridge, K.M. Verburg, et al.
Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.
Am J Cardiol, 89 (2002), pp. 425-430
[13.]
G. Singh, J.G. Fort, J.L. Goldstein, R.A. Levy, P.S. Hanrahan, A.E. Bello, et al.
for the SUCCESS-I Investigators Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
Am J Med, 119 (2006), pp. 255-266
[14.]
N. Arber, C.J. Eagle, J. Spicak, I. Racz, P. Dite, J. Hajer, et al.
PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps.
N Engl J Med, 355 (2006), pp. 885-895
[15.]
P. McGettigan, D. Henry.
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
[16.]
G.A. FitzGerald, C. Patrono.
The COXIBs, selective inhibitors of cyclooxygenase-2.
N Engl J Med, 345 (2001), pp. 433-442
[17.]
L.A. García Rodríguez, P. Patrignani.
The ever growing story of cyclooxygenase inhibition.
Lancet, 368 (2006), pp. 1745-1747
[18.]
C.P. Cannon, S.P. Curtis, G.A. FitzGerald, H. Krum, A. Kaur, J.A. Bolognese, for the MEDAL Steering Committee, et al.
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Lancet, 368 (2006), pp. 1771-1781
[19.]
F. Andersohn, S. Suissa, E. Garbe.
Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
Circulation, 113 (2006), pp. 1950-1957
[20.]
A. Helin-Salmivaara, A. Virtanen, R. Vesalainen, J.M. Gronroos, T. Klaukka, J.E. Idanpaan-Heikkila, et al.
NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland.
Eur Heart J, 14 (2006), pp. 1657-1663
[21.]
European Medicines Agency statement on the suspension of use of Bextra [nota de prensa]. European Medicines Agency; 7 abril 2005 [citado Nov 2006]. Disponible en: http://www.emea.eu.int/pdfs/human/press/pus/ 12163705en.pdf
[22.]
EMEA public statement on valdecoxib (Bextra/Valdyn) and parecoxib Sodium (Dynastat/Rayzon) Cardiovascular risks in coronary artery bypass graft (cabg) Surgery and serious adverse skin reactions [nota de prensa]. European Medicines Agency; 15 diciembre 2004 [citado Nov 2006]. Disponible en: http://www.emea.eu.int/pdfs/human/press/pus/20480204en.pdf
[23.]
N.A. Nussmeier, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, et al.
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
N Engl J Med, 352 (2005), pp. 1081-1091
[24.]
ADAPT Research Group.
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
PLoS Clin Trials, 1 (2006), pp. e33
[25.]
S. Hernández-Díaz, C. Varas-Lorenzo, L.A. García Rodríguez.
Nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Basic Clin Pharmacol Toxicol, 98 (2006), pp. 266-274
[26.]
F. Catella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. DeMarco, B. Tournier, et al.
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
N Engl J Med, 345 (2001), pp. 1809-1817
[27.]
T.M. MacDonald, L. Wei.
Effect of ibuprofen on cardioprotective effect of aspirin.
Lancet, 361 (2003), pp. 573-574
[28.]
T.N. Patel, K.C. Goldberg.
Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction.
Arch Intern Med, 164 (2004), pp. 852-856
[29.]
European Medicines Agency. CHMP review on non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) [citado Nov 2006]. Disponible en: http://www.emea.eu.int/htms/human/opiniongen/nsaids06.htm
[30.]
Agencia Española del Medicamento y Productos Sanitarios. Nota informativa de la Agencia Española del Medicamento sobre riesgos de tipo aterotrombótico de los Coxib y AINE tradicionales. 26 de octubre de 2006 [citado Nov 2006]. Disponible en: http://www.agemed.es/actividad/alertas/usoHumano/seguridad/coxibsoct06. htm
Copyright © 2007. Elsevier España S.L. Barcelona
Idiomas
Reumatología Clínica

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.